Boston Scientific Corp.

Marlborough-based Boston Scientific Corp. (NYSE: BSX) has initiated a clinical trial to evaluate the safety and effectiveness of the Lotus Valve System, designed to treat patients with severe aortic stenosis, a condition that prevents the aorta from opening fully.

Marlborough-based Boston Scientific Corp. (BSX) has received approval to sell its system designed to treat tremor disorders in the European Union, the company announced Wednesday.

Boston Scientific Corp. of Marlborough was ordered Wednesday to pay a Texas woman $73 million—including $50 million in punitive damages — after a jury found the company negligent in both the design and marketing of its Obtryx transvaginal mesh sling.

Boston Scientific has completed its purchase of the interventional business of Bayer AG, opening up the Marlborough-based company's treatment solutions for vascular conditions.

Boston Scientific of Marlborough and a Japanese firm will jointly develop a new product that will be used in Boston Scientific's Polaris Multi-Modality Imaging System that's used to treat heart patients.

Strong sales from several divisions, as well as international growth of 7 percent, were tarnished by heavy expenses as Boston Scientific Corp. (BSX) reported a 97-percent drop in profits in its second-quarter financial results.

Marlborough-based Boston Scientific Corp. has received federal approval for its latest stent system designed to treat coronary artery disease.

Boston Scientific has launched European sales of products designed to treat peripheral artery and aortic valve diseases.

Boston Scientific said last week its surgical treatment of Parkinson's disease has been found to improve motor scores and decrease medication usage.

On the heels of its recently announced acquisition of IoGyn Inc., Natick-based pharmaceutical company Boston Scientific Corp. (BSX) announced it will acquire the Interventional Division of Bayer AG for $415 million in cash.